Deep Genomics is a Toronto-based biotechnology company using artificial intelligence to develop RNA therapeutics. Their AI Workbench platform identifies genetic targets and designs oligonucleotide drugs more efficiently than traditional methods. Differentiators include proprietary machine learning models predicting how genetic mutations affect cell biology. Canadian operations are focused in Toronto, where R&D, bioinformatics, and drug discovery teams drive development of novel treatments for rare genetic diseases.